278 results on '"Lunghi, F."'
Search Results
2. L’industria dei radiofarmaci in Italia: produzione, importazione e distribuzione
3. A model arm for testing motor control theories on corrective movements during reaching
4. 2CTG2: A new system for the antepartum analysis of fetal heart rate
5. P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY
6. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19
7. Determinants of early triage for hospitalization in MPN patients with COVID-19
8. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors
9. Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia
10. EXTRACORPOREAL PHOTOAFERESIS: AN EFFECTIVE TREATMENT FOR CUTANEOUS MANIFESTATIONS OF STEROID-DEPENDENT AND STEROID-REFRACTORY GVHD: PH-AB241
11. T CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOLLOWED BY ADD-BACKS OF SUICIDE-GENE MODIFIED DONOR T-CELLS OFFERS LONG TERM SURVIVAL FREE OF IMMUNE SUPPRESSION TREATMENT: A 7 YEARS FOLLOW-UP IN 56 PATIENTS: PH-O084
12. Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer
13. Allogeneic transplantation in elderly patients with poor prognosis acute myeloid leukaemia or myelodysplastic syndrome; the San Raffaele Institute experience.: P1210
14. Treosulfan-based conditioning regimen allows an early full donor chimerism after related and unrelated transplant with low toxicity. Results from a prospective single-centre study: P972
15. Treosulfan-based conditioning regimen for allo-SCT in 283 patients: co-morbidity index and disease status are predictors of outcomes: P963
16. Anidulafungin primary prophylaxis in 28 high-risk patients undergoing allogeneic haematopoietic stem cell transplantation: a single-centre experience: P807
17. Pre-emptive treatment for CMV reactivation after allogeneic stem cell transplantation: a single-centre experience in 223 patients: P785
18. Quantitative real-time PCR evaluation of Wilms tumour gene transcript levels in autologous peripheral blood stem cell can predict the risk of acute myeloid leukaemia relapse after autologous transplantation: P743
19. Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy
20. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin
21. Feasibility and efficacy of allogeneic stem cell transplantation for refractory or relapsed myelodysplastic syndrome and secondary acute myeloid leukaemia: a single-centre experience
22. Haematopoietic stem cell transplantation in poor prognosis MDS and sAML: prolonged patients survival is achievable, but refining of infections management and reduction of treatment-related toxicities is required to improve patients outcome
23. Foscarnet as single agent pre-emptive treatment of cytomegalovirus reactivation after T-cell depleted allogeneic haematopoietic stem cell transplantation
24. Donor lymphocyte infusion from HLA-matched siblings outside of the context of a haematopoietic stem cell transplantation: a pilot study
25. Bone marrow mammaglobin expression as a tool for assessing micrometastatic disease after reduced-intensity allografting for advanced breast cancer
26. Risk factors for secondary cancer in a case-control study on 1,881 patients with myeloproliferative neoplasms (ELN Study)
27. S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY
28. PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS
29. Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis
30. Secondary solid tumors after allogeneic stem cell transplantation: active surveillance in long term follow-up
31. ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY
32. Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms
33. Observational Study of CML Italian Patients Who Discontinued TKIs
34. Standardized care of long-term survivors after allogeneic stem cell transplantation: a cross-sectional 1-year evaluation in 249 adults
35. Revealing the Generation of Human Memory Stem T Cells in Haploidentical T-Replete Hematopoietic Stem Cell Transplantation
36. TRACKING T CELL DYNAMICS IN THE FIRST MONTH AFTER ALLOGENEIC HSCT OFFERS A UNIQUE OPPORTUNITY TO UNVEIL THE MECHANISM OF MEMORY STEM T CELL FORMATION IN HUMANS
37. Cardiovascular events and intensity of treatment in polycythemia vera
38. Comparative evaluation of the predictive power of the EBMT risk score and the Hematopoietic Cell Transplantation Co-morbidity Index for allogeneic haematopoietic stem cell transplantation in a treosulfan-based conditioning setting
39. Pre-emptive treatment for CMV reactivation after allogeneic stem cell transplantation: a single-centre experience in 223 patients
40. Quantitative real-time PCR evaluation of Wilms tumour gene transcript levels in autologous peripheral blood stem cell can predict the risk of acute myeloid leukaemia relapse after autologous transplantation
41. Treosulfan-based conditioning regimen for allo-SCT in 283 patients: co-morbidity index and disease status are predictors of outcomes
42. Allogeneic transplantation in elderly patients with poor prognosis acute myeloid leukaemia or myelodysplastic syndrome; the San Raffaele Institute experience
43. Anidulafungin primary prophylaxis in 28 high-risk patients undergoing allogeneic haematopoietic stem cell transplantation: a single-centre experience
44. Implementation of an alternative donor is a prerequisite for a good intention-to-treat performance in patients in need of allogeneic transplantation: analysis of 361 patients
45. Timing and rate of success in transplant of matched unrelated donor (MUD) searches through bone marrow donors worldwide (BMDW): the case of San Raffaele Institute in 2006-2009
46. Monitoring of Willms' tumour gene 1 transcripts in AML and MDS patients can predict early relapse after allogeneic haematopoietic stem cell transplantation
47. THIOTEPA-CYCLOPHOSPHAMIDE HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE FORMS OF MULTIPLE SCLEROSIS: RESULTS IN 9 PATIENTS
48. ORAL VALGANCICLOVIR AS EARLY PRE-EMPTIVE TREATMENT FOR CMV REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE IN 45 PATIENTS
49. SECOND ALLOGENEIC STEM CELL TRANSPLANTATION AS SALVAGE TREATMENT IN RELAPSED HAEMATOLOGICAL MALIGNANCIES: FEASIBILITY AND OUTCOME IN 26 PATIENTS
50. Combination of fludarabine and cytarabine as induction treatment of poor prognosis myelodysplastic syndrome (MDS) and secondary acute myeloid leukaemia (sAML): a single centre experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.